{{Rsnum
|rsid=4148947
|Gene=CHST3
|Chromosome=10
|position=73770117
|Orientation=plus
|GMAF=0.3177
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=132
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 24.8 | 50.4 | 24.8
| HCB | 0.7 | 20.4 | 78.8
| JPT | 1.8 | 23.0 | 75.2
| YRI | 5.4 | 32.0 | 62.6
| ASW | 21.1 | 33.3 | 45.6
| CHB | 0.7 | 20.4 | 78.8
| CHD | 1.8 | 15.6 | 82.6
| GIH | 14.9 | 38.6 | 46.5
| LWK | 7.3 | 41.8 | 50.9
| MEX | 17.2 | 44.8 | 37.9
| MKK | 3.8 | 40.4 | 55.8
| TSI | 24.5 | 47.1 | 28.4
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4148947
|Name_s=CHST3:rs4148947 C>T; NM_004273.3:c.*1888T>C
|Gene_s=CHST3
|Feature=3' UTR
|Evidence=PubMed ID:20038957
|Annotation=Risk or phenotype-associated allele: C Phenotype: The CHST3:rs4148947 C variant was associated with positive clincial response (partial or complete response) to treatment. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.0023 Type of association: PD; CO
|Drugs=docetaxel; thalidomide
|Drug Classes=
|Diseases=Prostatic Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA165111529
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4148947
|overall_frequency_n=42
|overall_frequency_d=128
|overall_frequency=0.328125
|n_genomes=29
|n_genomes_annotated=0
|n_haplomes=39
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}